Human leishmaniasis is a tropical parasitic disease that remains a serious public health problem worldwide. It can also be fatal if left untreated, especially when it progresses to the visceral form. To date, there is still no vaccine available to prevent leishmaniasis. The current treatments available to combat leishmaniasis are inadequate, toxic, expensive, require repeated injectable applications, and are not effective against all species. Extracts from Ricinodendron heudelotii, Enantia polycarpa, Kigelia africana, and Adenia cissampeloides have been evaluated for their ability to inhibit the growth of Leishmania donovani promastigotes. The results show that E. polycarpa has the lowest IC50 at 4.79±1.02 µg/mL, indicating strong antipromastigote activity. In contrast, R. heudelotii and K. africana exhibit respective IC50 values of 95.10±1.57 µg/mL and 79.44±2.12 µg/mL, suggesting lower efficacy. A. cissampeloides did not show significant activity, with an IC50 greater than 100 µg/mL. The activity of E. polycarpa is likely due to the presence of polyphenols and alkaloids it contains.